|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
KFL011086807 |
| 003 |
DE-627 |
| 005 |
20230713210608.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
230609s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.4155/bio-2021-0243
|2 doi
|
| 035 |
|
|
|a (DE-627)KFL011086807
|
| 035 |
|
|
|a (KFL)prod_FICIBQ_10.4155/bio-2021-0243
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 084 |
|
|
|a PHARM
|q DE-84
|2 fid
|
| 100 |
1 |
|
|a Briscoe, Chad J
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Special Focus Issue - COVID-19: bioanalytical considerations, contributions and lessons – part 2
|c Chad J Briscoe, Matthew Barfield
|
| 264 |
|
1 |
|a [Erscheinungsort nicht ermittelbar]
|c 2021
|
| 300 |
|
|
|a 1 Online-Ressource (2 p)
|
| 336 |
|
|
|a nicht spezifiziert
|b zzz
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 653 |
|
|
|a bioanalysis
|
| 653 |
|
|
|a COVID-19
|
| 653 |
|
|
|a laboratory
|
| 700 |
1 |
|
|a Barfield, Matthew
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Bioanalysis
|d London : Future Science, 2009
|h Online-Ressource
|w (DE-627)KFL000038172
|w (DE-600)2571813-7
|w (DE-576)398101434
|x 1757-6199
|7 nnns
|
| 856 |
4 |
0 |
|u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.4155/bio-2021-0243
|m X:KFL
|x Resolving-System
|y FID Access
|z lizenzpflichtig
|
| 912 |
|
|
|a GBV_KFL
|
| 912 |
|
|
|a FID-PHARM
|
| 935 |
|
|
|i IMPORT_0628_prod_FICIBQ_03
|
| 951 |
|
|
|a AR
|
